EMA and FDA Accept UCB’s Marketing Applications for Bimekizumab
FDA and EMA have accepted the biologics license application and marketing authorization application, respectively, for bimekizumab.
Global biopharmaceutical company, UCB, has announced that the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the biologics license application (BLA) and marketing authorization application (MAA), respectively, for bimekizumab.
In a Sept. 22, 2020 press release, the company revealed that the application submissions have been accepted for the investigational humanized monoclonal IgG1 antibody, bimekizumab, to be used as a treatment for adults with moderate to severe plaque psoriasis. The applications were based on data from a global Phase III clinical development program.
“After a series of positive Phase III data readouts, we are delighted to announce that the US FDA and EMA have accepted our applications to file bimekizumab as a potential new treatment for psoriasis,” said Emmanuel Caeymaex, executive vice-president Immunology Solutions and head of US, UCB, in the press release. “This milestone brings us one step closer to being able to offer a meaningful new treatment option for people living with this debilitating disease. UCB is committed to providing innovative solutions for people living with serious inflammatory diseases like psoriasis.”
Evaluation of the safety and efficacy of bimekizumab are still ongoing and the drug is not yet approved by any regulatory authority worldwide. The drug is also under evaluation for potential indications in psoriatic arthritis.
Source: UCB
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
